External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

2026 ASCO® Gastrointestinal Cancers Symposium

January 08 - January 10

San Francisco, USA / Virtual (Hybrid)

conferences.asco.org

We will be contributing to topics related to

Oncology

Add to calendar

Agenda

Medical Materials

07:30 PM

Duration 90mins San Francisco, USA

A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC)

Richard Kim, Anwaar Saeed, William J. Chapin, Kevin Kim, Renuka Iyer, Robert Martin, Axel Grothey, Saikrishna Gadde, Lynn Feun, Afshin Eli Gabayan, Yvonne Saenger, Maen Abdelrahim, Nalini Govada, Ben Xie, May Cho, Adam Burgoyne

Oncology | Liver Cancer

Notify me

Add to calendar

03:00 PM

Duration 55mins San Francisco, USA

Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for PIK3CA-mutated (mut) metastatic colorectal cancer (mCRC)

Marwan Fakih, Eric Chen, Keun-Wook Lee, Tanios Bekaii-Saab, Sara Lonardi, Jun Gong, Elena Elez, Janet Lau, Vanessa Breton, Omara Khan, Olga Chertkova, Saket Jain, Sae Won Han

Oncology | Pancreatic Cancer

Notify me

Add to calendar

Coming soon

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.